市場調査レポート

商品コード

1593762

骨粗鬆症治療の世界市場の評価：薬剤タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別、機会、予測（2017年～2031年）

Osteoporosis Treatment Market Assessment, By Drug Type, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年11月20日
発行: Market Xcel - Markets and Data
ページ情報: 英文 236 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 703,125円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 890,625円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,281,250円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.25円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の骨粗鬆症治療の市場規模は、2023年の147億9,000万米ドルから2031年に214億4,000万米ドルに達すると予測され、予測期間の2024年～2031年にCAGRで4.75%の成長が見込まれます。市場は、骨粗鬆症治療の疾病負担の増大、高齢化、この分野で進行している医薬品開発・承認活動により、今後の成長が見込まれています。

骨粗鬆症は、骨密度の低下と骨折リスクの増加を特徴とする骨の疾患です。治療アプローチには、骨を強化し骨折リスクを低減するための生活習慣の改善（食事療法、運動療法）、薬物療法（ビスフォスフォネート系薬剤、ホルモン療法、モノクローナル抗体）、サプリメント（カルシウム、ビタミンD）などがあります。市場は、世界の骨粗鬆症患者の増加と、骨粗鬆症患者への治療オプションの改善の影響を受けて成長すると予測されます。政府やその他のステークホルダーによる複数の取り組みが、市場の成長率をさらに高めています。近年の動向としては、薬理学的治療と栄養や運動のような生活習慣の改善を組み合わせた個別化医療が注目されています。ドラッグデリバリーシステムの革新や新しい治療薬の継続的な研究により、市場の成長はさらに高まると予測されます。治療のアドヒアランスや副作用といった課題は依然として残っており、継続的な患者教育とサポートの必要性が浮き彫りになっています。市場は、人口動態の変化や医学研究と技術の進歩に後押しされ、成長が見込まれています。

例えば2024年8月、ロンドンのNational Institute for Health and Care Excellence（NICE）は、骨折リスクの非常に高い閉経後女性の骨粗鬆症に対する新たな治療オプションとしてアバロパラチドを推奨し、1万4,000人超に恩恵をもたらしました。Theramex HQ UK LimitedからEladynosとして販売されているこの薬剤は、骨形成を促進することにより骨密度を高めます。標準的な治療に反応しない、あるいは耐容性がない場合の代替薬として使用されます。

当レポートでは、世界の骨粗鬆症治療市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

市場規模の分析と予測
- 金額
市場シェアの分析と予測
- 薬剤タイプ別
- 薬剤クラス別
- 投与経路別
- 流通チャネル別
- 地域別
- 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
市場マップ分析（2023年）
- 薬剤タイプ別
- 薬剤クラス別
- 投与経路別
- 流通チャネル別
- 地域別

第5章北米の骨粗鬆症治療市場の見通し（2017年～2031年）

市場規模の分析と予測
- 金額
市場シェアの分析と予測
- 薬剤タイプ別
- 薬剤クラス別
- 投与経路別
- 流通チャネル別
- シェア：国別
各国の市場の評価
- 米国の骨粗鬆症治療市場の見通し（2017年～2031年）
- カナダ
- メキシコ

第6章欧州の骨粗鬆症治療市場の見通し（2017年～2031年）

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
ポーランド

第7章アジア太平洋の骨粗鬆症治療市場の見通し（2017年～2031年）

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第8章南米の骨粗鬆症治療市場の見通し（2017年～2031年）

ブラジル
アルゼンチン

第9章中東・アフリカの骨粗鬆症治療市場の見通し（2017年～2031年）

サウジアラビア
アラブ首長国連邦
南アフリカ
イスラエル

第10章需給分析

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第13章 PESTLE分析

第14章価格分析

第15章市場力学

市場促進要因
市場の課題

第16章市場の動向と発展

第17章規制枠組みとイノベーション

臨床試験
規制当局の承認

第18章特許情勢

第19章ケーススタディ

第20章競合情勢

マーケットリーダー上位5社の競合マトリクス
上位5社のSWOT分析
主要企業上位10社の情勢
- Novartis AG
- Eli Lilly and Company
- Amgen, Inc.
- Viatris Inc.
- Pfizer, Inc.
- GlaxoSmithKline plc.
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Sanofi S.A.

第21章戦略的推奨

第22章当社について、免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 3. Global Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 4. Global Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 5. Global Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 6. Global Osteoporosis Treatment Market Share (%), By Region, 2017-2031F
Figure 7. North America Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 8. North America Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 9. North America Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 10. North America Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 11. North America Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 12. North America Osteoporosis Treatment Market Share (%), By Country, 2017-2031F
Figure 13. United States Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 14. United States Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 15. United States Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 16. United States Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 17. United States Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 18. Canada Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 19. Canada Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 20. Canada Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 21. Canada Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 22. Canada Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 23. Mexico Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 24. Mexico Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 25. Mexico Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 26. Mexico Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 27. Mexico Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 28. Europe Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 29. Europe Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 30. Europe Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 31. Europe Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 32. Europe Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 33. Europe Osteoporosis Treatment Market Share (%), By Country, 2017-2031F
Figure 34. Germany Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 35. Germany Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 36. Germany Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 37. Germany Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 38. Germany Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 39. France Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 40. France Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 41. France Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 42. France Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 43. France Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 44. Italy Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 45. Italy Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 46. Italy Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 47. Italy Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 48. Italy Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 49. United Kingdom Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 50. United Kingdom Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 51. United Kingdom Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 52. United Kingdom Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 53. United Kingdom Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 54. Russia Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 55. Russia Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 56. Russia Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 57. Russia Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 58. Russia Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 59. Netherlands Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 60. Netherlands Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 61. Netherlands Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 62. Netherlands Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 63. Netherlands Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 64. Spain Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 65. Spain Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 66. Spain Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 67. Spain Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 68. Spain Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 69. Turkey Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 70. Turkey Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 71. Turkey Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 72. Turkey Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 73. Turkey Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 74. Poland Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 75. Poland Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 76. Poland Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 77. Poland Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 78. Poland Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 79. South America Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 80. South America Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 81. South America Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 82. South America Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 83. South America Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 84. South America Osteoporosis Treatment Market Share (%), By Country, 2017-2031F
Figure 85. Brazil Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 86. Brazil Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 87. Brazil Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 88. Brazil Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 89. Brazil Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 90. Argentina Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 91. Argentina Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 92. Argentina Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 93. Argentina Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 94. Argentina Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 95. Asia-Pacific Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 96. Asia-Pacific Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 97. Asia-Pacific Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 98. Asia-Pacific Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 99. Asia-Pacific Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 100. Asia-Pacific Osteoporosis Treatment Market Share (%), By Country, 2017-2031F
Figure 101. India Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 102. India Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 103. India Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 104. India Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 105. India Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 106. China Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 107. China Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 108. China Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 109. China Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 110. China Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 111. Japan Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 112. Japan Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 113. Japan Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 114. Japan Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 115. Japan Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 116. Australia Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 117. Australia Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 118. Australia Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 119. Australia Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 120. Australia Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 121. Vietnam Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 122. Vietnam Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 123. Vietnam Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 124. Vietnam Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 125. Vietnam Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 126. South Korea Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 127. South Korea Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 128. South Korea Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 129. South Korea Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 130. South Korea Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 131. Indonesia Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 132. Indonesia Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 133. Indonesia Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 134. Indonesia Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 135. Indonesia Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 136. Philippines Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 137. Philippines Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 138. Philippines Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 139. Philippines Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 140. Philippines Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 141. Middle East & Africa Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 142. Middle East & Africa Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 143. Middle East & Africa Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 144. Middle East & Africa Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 145. Middle East & Africa Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 146. Middle East & Africa Osteoporosis Treatment Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 148. Saudi Arabia Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 149. Saudi Arabia Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 150. Saudi Arabia Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 151. Saudi Arabia Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 152. UAE Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 153. UAE Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 154. UAE Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 155. UAE Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 156. UAE Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 157. South Africa Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 158. South Africa Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
Figure 159. South Africa Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
Figure 160. South Africa Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
Figure 161. South Africa Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
Figure 162. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX12274

Global osteoporosis treatment market is projected to witness a CAGR of 4.75% during the forecast period 2024-2031, growing from USD 14.79 billion in 2023 to USD 21.44 billion in 2031. The osteoporosis treatment market is poised for future growth due to the increasing disease burden of osteoporosis treatment, the aging population, and ongoing drug development and approval activities in the field.

Osteoporosis is a bone disease characterized by decreased bone density and increased fracture risk. Treatment approaches include lifestyle modifications (diet, exercise), medications (bisphosphonates, hormone therapies, and monoclonal antibodies), and supplements (calcium, vitamin D) to strengthen bones and reduce fracture risk. The market for osteoporosis drugs is anticipated to thrive under the influence of rising osteoporosis cases globally and improved treatment options available for osteoporotic patients. Several initiatives from the government and other stakeholders further strengthen the growth rate in the market. Recent trends include a focus on personalized medicine, combining pharmacological treatments with lifestyle modifications like nutrition and exercise. Innovations in drug delivery systems and ongoing research into new therapeutic agents are expected to enhance market growth further. Challenges such as treatment adherence and side effects persist, underscoring the need for ongoing patient education and support. The osteoporosis treatment market is poised for growth, fueled by demographic shifts and advancements in medical research and technology.

For instance, in August 2024, the National Institute for Health and Care Excellence (NICE), London, recommended abaloparatide as a new treatment option for osteoporosis in postmenopausal women at very high fracture risk, benefiting over 14,000 individuals. This drug, marketed as Eladynos by Theramex HQ UK Limited, enhances bone density by stimulating bone formation. It serves as an alternative for those who do not respond to or tolerate standard treatments.

Rising Prevalence of Osteoporosis and Improved Treatment Options to Boost Market Demand

The major driving factor of the osteoporosis treatment market has been the increase in the incidence of the disease among the elderly. The greater recognition of the condition has led to more patients seeking effective therapy to prevent fractures and allow the bones to become healthy again. In addition, improved treatment options, such as the introduction of bisphosphonates, hormone therapies, and newer biologics, reinforce the increased demand for these products. More attention from healthcare providers and organizations toward early diagnosis and preventive care is motivating patients to seek treatment. Personalized medicine further increases the appeal of osteoporosis therapies that are treated uniquely for every patient. With the increasing number of the aging population and the related risk of osteoporosis, the treatment for osteoporosis has become a rapidly growing and potential market. With the rising emphasis on bone health, the promising area for effective and innovative osteoporotic therapy will increase even further, pointing out the clear priority for pharmaceutical companies. According to the International Osteoporosis Foundation, osteoporosis affects approximately 6.3% of men over the age of 50 and 21.2% of women over the same age range globally, and 37 million fragility fractures occur annually in osteoporosis patients aged over 55.

Government Initiatives for Osteoporosis Treatment Drive Market Growth

Government-led programs and policies support the osteoporosis treatment market growth. Public health education programs enhance awareness about disease and its risk factors. A variety of updated guidelines on routine screening that facilitate early diagnosis and timely interventions for postmenopausal women and older adults further boost the demand for treatment. Furthermore, public funding for research on the disease also pushes the discovery of novel treatments and developments in existing treatments, encouraging pharmaceutical firms to invest in this area. Coordination between government health departments and healthcare providers will be improved education and training, improving the treatment of osteoporosis, and patient compliance with treatment. Improved policies that increase reimbursement for the treatment of osteoporosis enhance access to care and encourage more patients to seek care. For instance, in July 2024, The Centers for Medicare & Medicaid Services (CMS) proposed a 2025 Physician Fee Schedule aimed at enhancing post-fracture care for the 10 million Americans with osteoporosis. This initiative, supported by various health organizations, seeks to incentivize better care and reduce the rising costs associated with osteoporotic fractures, projected to reach USD 95 billion by 2040. Key changes include new coding for fracture management and a call for public comment to improve evidence-based care access, particularly for disproportionately affected women.

Bisphosphonate Segment to Dominate Market

The bisphosphonate class of drugs is anticipated to dominate the osteoporosis treatment market because drugs like alendronate and risedronate have proven to have an established efficacy in reducing fracture risk and, therefore, are trusted by clinicians. Other bisphosphonates are also available as generic equivalents, making them more accessible and adaptable. More often, bisphosphonates are highly regulated under clinical guidelines, and therefore, their regulated use among healthcare providers is ensured. They also tend to have a more benign safety profile compared with other newer treatments, together with a longer duration of action that permits less frequent dosing, thereby improving compliance in the patient. Ongoing studies concerning their long-term effect also help to support their clinical use further and thus remain an integral part of treatment protocols.

For instance, in March 2024, Sandoz Group AG received FDA approval for two biosimilars, Jubbonti and Wyost, targeting Amgen Inc.'s denosumab, a key treatment for osteoporosis. Jubbonti will compete with Prolia, aimed at high-risk osteoporotic men and postmenopausal women, and is also indicated for glucocorticoid-induced osteoporosis. Wyost will challenge Xgeva, which is used to prevent skeletal-related events in cancer patients. Both biosimilars have interchangeable status, allowing easy substitution without prescription changes. While this development promises improved access to essential osteoporosis treatments, Sandoz has not disclosed launch dates or pricing due to ongoing patent litigation.

North America Dominates Osteoporosis Treatment Market

The North America osteoporosis treatment market is important, as the population in this market is more aged, which leads to a greater incidence of osteoporosis and related fractures. Moreover, increased awareness of the disease by healthcare providers and patients has led to increased testing, evaluation, and treatment, which has driven this burgeoning market. Advances in healthcare infrastructure in the region provide easy access to the latest medical technologies, thus making the development and distribution of effective treatments for osteoporosis easier. Insurance coverage and reimbursement policies are other key factors driving the market. Some health insurance covers osteoporosis medications for many patients, hence increasing adherence to the treatment. Regulatory agencies, like the USFDA, ensure new therapies are placed under an adequate check, ensuring more confidence in treatment safety and efficacy.

For instance, in February 2024, the USFDA added a Boxed Warning to Prolia (denosumab), indicating an increased risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD), particularly those on dialysis. This risk is heightened in patients with CKD-mineral and bone disorders. The warning aims to ensure proper patient selection and monitoring, as severe hypocalcemia can lead to serious health complications, including hospitalization and death.

Future Market Scenario (2024-2031F)

Bone-targeting nanoparticles represent a groundbreaking advancement in the treatment of osteoporosis by increasing drug delivery specifically to bone tissue. Traditional osteoporosis medications often suffer from low targeting specificity, leading to systemic toxicity and reduced efficacy. In contrast, these nanoparticles can be engineered to recognize and bind to bone tissue, ensuring that therapeutic agents are delivered precisely where needed. The nanoparticles can encapsulate various therapeutic agents, including growth factors and nucleic acids, improving their bioavailability and stability. Their small size allows for better penetration into biological barriers, while modifications can enhance their affinity for bone surfaces. For instance, lipid nanocarriers and exosomes have shown promise in delivering anti-osteoporotic agents directly to osteoblasts, promoting bone formation and inhibiting osteoclast activity. This targeted approach minimizes side effects and maximizes therapeutic outcomes, paving the way for more effective osteoporosis treatments in the future.

Key Players Landscape and Outlook

Global pharmaceutical giants like Pfizer, Inc., Novartis AG, and many more mainly dominate the market for osteoporosis treatment. The drugs used for osteoporosis include branded and generic versions, and smaller market players cater the generic equivalents. Recent market activities include regulatory approvals and recommendations, along with acquisitions.

In July 2024, Bone Health Technologies, Inc. (BHT) acquired Wellen, a Brooklyn-based company specializing in personalized exercise programs for osteoporosis in women over 50. This acquisition aims to enhance BHT's offerings by integrating Wellen's expertise with BHT's upcoming Osteoboost vibration therapy belt, set to launch in late 2024. The combined approach seeks to provide effective, non-drug solutions for osteoporosis and osteopenia, addressing a significant public health issue affecting millions globally.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Osteoporosis Treatment Market Outlook, 2017-2031F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Drug Type
  - 4.2.1.1. Generic
  - 4.2.1.2. Branded
- 4.2.2. By Drug Class
  - 4.2.2.1. Bisphosphonate
  - 4.2.2.2. Hormone Replacement Therapy
    - 4.2.2.2.1. Parathyroid Hormone
    - 4.2.2.2.2. Calcitonin
  - 4.2.2.3. Selective Estrogen Receptor Modulator (SERM)
  - 4.2.2.4. Rank ligand Inhibitor (RANKL)
  - 4.2.2.5. Others
- 4.2.3. By Route of Administration
  - 4.2.3.1. Oral
  - 4.2.3.2. Parenteral
- 4.2.4. By Distribution Channel
  - 4.2.4.1. Hospital and Clinics
  - 4.2.4.2. Retail Pharmacies
  - 4.2.4.3. Online Pharmacies
- 4.2.5. By Region
  - 4.2.5.1. North America
  - 4.2.5.2. Europe
  - 4.2.5.3. Asia-Pacific
  - 4.2.5.4. South America
  - 4.2.5.5. Middle East and Africa
- 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
4.3. Market Map Analysis, 2023
- 4.3.1. By Drug Type
- 4.3.2. By Drug Class
- 4.3.3. By Route of Administration
- 4.3.4. By Distribution Channel
- 4.3.5. By Region

5. North America Osteoporosis Treatment Market Outlook, 2017-2031F*

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Drug Type
  - 5.2.1.1. Generic
  - 5.2.1.2. Branded
- 5.2.2. By Drug Class
  - 5.2.2.1. Bisphosphonate
  - 5.2.2.2. Hormone Replacement Therapy
    - 5.2.2.2.1. Parathyroid Hormone
    - 5.2.2.2.2. Calcitonin
  - 5.2.2.3. Selective Estrogen Receptor Modulator (SERM)
  - 5.2.2.4. Rank ligand Inhibitor (RANKL)
  - 5.2.2.5. Others
- 5.2.3. By Route of Administration
  - 5.2.3.1. Oral
  - 5.2.3.2. Parenteral
- 5.2.4. By Distribution Channel
  - 5.2.4.1. Hospital and Clinics
  - 5.2.4.2. Retail Pharmacies
  - 5.2.4.3. Online Pharmacies
- 5.2.5. By Country Share
  - 5.2.5.1. United States
  - 5.2.5.2. Canada
  - 5.2.5.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Osteoporosis Treatment Market Outlook, 2017-2031F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Drug Type
      - 5.3.1.2.1.1. Generic
      - 5.3.1.2.1.2. Branded
    - 5.3.1.2.2. By Drug Class
      - 5.3.1.2.2.1. Bisphosphonate
      - 5.3.1.2.2.2. Hormone Replacement Therapy
      - 5.3.1.2.2.2.1. Parathyroid Hormone
      - 5.3.1.2.2.2.2. Calcitonin
      - 5.3.1.2.2.3. Selective Estrogen Receptor Modulator (SERM)
      - 5.3.1.2.2.4. Rank ligand Inhibitor (RANKL)
      - 5.3.1.2.2.5. Others
    - 5.3.1.2.3. By Route of Administration
      - 5.3.1.2.3.1. Oral
      - 5.3.1.2.3.2. Parenteral
    - 5.3.1.2.4. By Distribution Channel
      - 5.3.1.2.4.1. Hospital and Clinics
      - 5.3.1.2.4.2. Retail Pharmacies
      - 5.3.1.2.4.3. Online Pharmacies
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Osteoporosis Treatment Market Outlook, 2017-2031F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland

7. Asia-Pacific Osteoporosis Treatment Market Outlook, 2017-2031F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Osteoporosis Treatment Market Outlook, 2017-2031F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Osteoporosis Treatment Market Outlook, 2017-2031F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

15.1. Market Drivers
15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

17.1. Clinical Trials
17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

20.1. Competition Matrix of Top 5 Market Leaders
20.2. SWOT Analysis for Top 5 Players
20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. Novartis AG
  - 20.3.1.1. Company Details
  - 20.3.1.2. Key Management Personnel
  - 20.3.1.3. Products and Services
  - 20.3.1.4. Financials (As Reported)
  - 20.3.1.5. Key Market Focus and Geographical Presence
  - 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
- 20.3.2. Eli Lilly and Company
- 20.3.3. Amgen, Inc.
- 20.3.4. Viatris Inc.
- 20.3.5. Pfizer, Inc.
- 20.3.6. GlaxoSmithKline plc.
- 20.3.7. AbbVie, Inc.
- 20.3.8. Teva Pharmaceutical Industries Ltd.
- 20.3.9. Merck & Co., Inc.
- 20.3.10. Sanofi S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

骨粗鬆症治療の世界市場の評価：薬剤タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別、機会、予測（2017年～2031年）

Osteoporosis Treatment Market Assessment, By Drug Type, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の骨粗鬆症治療市場の見通し（2017年～2031年）

第5章 北米の骨粗鬆症治療市場の見通し（2017年～2031年）

第6章 欧州の骨粗鬆症治療市場の見通し（2017年～2031年）

第7章 アジア太平洋の骨粗鬆症治療市場の見通し（2017年～2031年）

第8章 南米の骨粗鬆症治療市場の見通し（2017年～2031年）

第9章 中東・アフリカの骨粗鬆症治療市場の見通し（2017年～2031年）

第10章 需給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析